Turkey is set to become one of the first countries in the world to implement IVF automation at a national scale, following a landmark commercial agreement between Overture Life and Tekservis. The partnership will roll out Overture Life's DaVitri Automated Egg and Embryo Freezing platform across fertility clinics throughout the country, a move that signals a pivotal shift in how reproductive medicine is being delivered and standardized on a large scale.

Overture Life, a leading developer of automated IVF technologies and the first company to have achieved live births from both robotic fertilization and robotic egg freezing, made the announcement on June 11, 2026. The collaboration with Tekservis will give clinics across Turkey immediate access to standardized vitrification technology, positioning the country as an early proving ground for a model of care built on reproducibility and throughput.

IVF at a Crossroads

The timing of this deployment reflects broader structural pressures that have been building within the IVF industry for years. Historically, outcomes in fertility treatment have rested heavily on the skills of individual embryologists performing highly sensitive procedures by hand. That model has been responsible for millions of successful births worldwide. However, it has also introduced an inherent inconsistency across clinics and placed an upper ceiling on how rapidly high-quality care can be scaled to meet growing demand.

As delayed family formation becomes more common and fertility preservation gains wider adoption, those structural limitations are only becoming harder to ignore. Just as researchers continue to develop tools like three-dimensional models of the human uterus to observe embryo implantation and better understand IVF success rates, the clinical side of the industry is under equal pressure to modernize its laboratory workflows.

Hans Gangeskar, CEO of Overture Life, framed the problem in direct terms: "Right now, two women can walk into two different clinics, go through the same procedure, pay the same price, and get completely different outcomes based on who's at the bench that day. That's the problem we're solving. Every woman's eggs deserve the same standard of care."

How DaVitri Works

At the center of the partnership is the DaVitri platform, which targets vitrification, widely regarded as one of the most technically demanding steps in the entire IVF process. The platform deploys a microfluidic system that precisely controls both cryoprotectant exposure and timing throughout the freezing process, replacing the manual handling that has long defined this step with software-governed protocols.

The practical result is a significant reduction in operator-dependent variation. Clinics using DaVitri can increase procedural consistency and improve throughput without a proportional increase in staffing demands. Importantly, the same platform also handles embryo vitrification, which means standardization now extends across both fertility preservation cycles and active IVF treatment, moving the entire laboratory closer to what Overture Life describes as a fully reproducible IVF environment.

This drive toward laboratory-wide standardization also complements the broader scientific push to understand and improve implantation outcomes, including efforts to use models of the human uterus to observe embryo implantation under controlled conditions. The convergence of lab automation with deeper biological insight represents a two-pronged push to reduce the unpredictability that has long been part of IVF.

Turkey as a National Reference Market

Cemalettin Tombuloglu, General Manager at Tekservis, explained the commercial rationale driving the rollout. "Demand for fertility preservation and IVF treatment in Turkey is growing, and women coming to our clinics expect world-class outcomes. Overture has built technology that removes the variability that has always been part of this process. Our job is to make sure every clinic in our network can offer that, and offer it now."

Turkey's positioning as a significant fertility market and an emerging regional hub for reproductive care makes it a natural candidate to serve as a national reference point for this kind of large-scale automation deployment. The initial rollout will concentrate on vitrification, building on existing fertilization deployments already in place within the network. From there, further expansion will depend on regulatory pathways, clinic integration timelines, and continued clinical validation.

Broader Implications for Global IVF

The significance of the Overture Life and Tekservis agreement extends well beyond Turkey's borders. Healthcare systems and fertility networks globally are wrestling with how to absorb rising patient demand without allowing outcome variability to increase in step with volume. By transitioning from pilot-stage automation to commercial-scale deployment, this partnership offers one of the clearest real-world answers yet to that challenge.

The shift matters partly because so much of the scientific progress happening in parallel from advanced research using models of the human uterus to observe embryo implantation to AI-driven embryo selection tools depends on clinical environments that can deliver consistent, reproducible conditions at scale. Automation and scientific advancement, in this context, are not separate tracks but deeply interconnected ones.